Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4555)	6/25/1998 1:39:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Peter: I said "not positive", not "bad". Rick

To: Peter Singleton who wrote (4555)	6/25/1998 5:09:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 6136

Peter, this is my (naive) seat of the pants attempt to read Rick's mind on this issue: It would be good for Remune if it somehow ended up producing the same effect as the new Pitt therapy. The fact that Remune, by design, is unlikely to create a gp-120 dependent response may mean that it will not fully "mimic" the Pitt therapy. As Rick later said, not "bad news," but not as good as it could be either. Not sure if it has been mentioned here before, but the July issue of Scientific American has a series of articles on "Defeating AIDS" Of particular interest is the article by Baltimore and Heilman on prospects for HIV vaccines. Perhaps not much new for those who follow the field closely, but useful for the rest of us. PB